Impact of Brokerage Rating on NuVasive, Inc.(NUVA)

Many NuVasive, Inc.(NUVA) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. NuVasive was Initiated by Aegis Capital on Nov 30, 2016 to Buy, Price Target of the shares are set at $72.

Company has reported several Insider transactions to the SEC, on Dec 14, 2016, Matthew Link (President, U.S. Commercial) sold 10,303 shares at 67.99 per share price.On Nov 8, 2016, Michael D Ohalleran (director) purchased 4,200 shares at 58.26 per share price.On Nov 2, 2016, Joan Stafslien (EVP and General Counsel) purchased 5,000 shares at 59.68 per share price.

NuVasive Last issued its quarterly earnings results on Feb 9, 2017. The company reported $0.53 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $0.50. The company had revenue of $271.10 million for the quarter, compared to analysts expectations of $264.00 million. The companys revenue was up 25.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.35 EPS.

NuVasive, Inc. (NASDAQ:NUVA) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.29 by 14 Brokerage Firm. 12 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold.

NuVasive, Inc. (NASDAQ:NUVA): According to 11 Analysts, The short term target price has been estimated at $ 75.18.The target price could deviate by a maximum of $4.77 from the forecast price. In the near term, the target price could hit a high of $84 and a low of $ 70.

NuVasive, Inc. (NASDAQ:NUVA) rose 0.41% or 0.3 points on Tuesday and made its way into the gainers of the day. After trading began at $71.53 the stock was seen hitting $74.22 as a peak level and $71.1276 as the lowest level. The stock ended up at $74.04. The daily volume was measured at 1,132,513 shares. The 52-week high of the share price is $74.4 and the 52-week low is $37.95. The company has a market cap of $3,746 million.

NUVASIVE is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Companys product portfolio is focused on applications in the over $4.2 billion U.S. spine fusion market. The Companys current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS, as well as a growing offering of cervical and motion preservation products.

NuVasive,

Share this post

Post Comment